The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization

Massacesi, Amedeo; Sacchi, Laura; Bergamini, F.; Bottoni, Ferdinando

doi:10.1007/s00417-007-0638-x

Cited by 27 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our patient, intravitreal ranibizumab stopped the progression of the CNV-related disease, and visual acuity improved significantly, at least in the short term. Type 3 CNV is becoming an important cause of CNV, and unfortunately to date treatment of these lesions remains a difficult problem [5,[8][9] . Nevertheless, early diagnosis of type 3 CNV is easier with dynamic indocyanine green angiography and it has been reported to be associated with a better anatomical and functional prognosis after treatment [9] .…”

Section: Discussionmentioning

confidence: 99%

“…Type 3 CNV is becoming an important cause of CNV, and unfortunately to date treatment of these lesions remains a difficult problem [5,[8][9] . Nevertheless, early diagnosis of type 3 CNV is easier with dynamic indocyanine green angiography and it has been reported to be associated with a better anatomical and functional prognosis after treatment [9] . It is important for clinicians to recognize the anatomic features and the early manifestations of this peculiar form of CNV so that a proper diagnosis can be made and, when possible, an appropriate management administered.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Type 3 Choroidal Neovascularization Associated with Fundus Flavimaculatus

et al. 2009

View full text Add to dashboard Cite

Aim: To describe a patient with type 3 choroidal neovascularization (CNV) associated with fundus flavimaculatus (FFM), who underwent treatment with intravitreal ranibizumab. Methods: A 78-year-old woman diagnosed with FFM presented at our department complaining of decreased vision and metamorphopsia in her left eye. Upon a complete ophthalmologic examination, including best corrected visual acuity (BCVA), fundus autofluorescence, fluorescein angiography (FA), indocyanine green angiography (ICGA), and spectral domain optical coherence tomography (SD-OCT), the patient was diagnosed with type 3 CNV associated with FFM, and was submitted to intravitreal ranibizumab injections at monthly intervals. Results: Six months after 3 monthly injections of ranibizumab, the patient’s BCVA improved from 20/64 to 20/32. FA and ICGA revealed a type 3 CNV closure, and the SD-OCT scan showed a fibrous scar replacing the type 3 CNV, with resolution of serous retinal detachment. Conclusion: This case represents the first demonstration of type 3 CNV associated with FFM. Based on our findings, intravitreal ranibizumab may be considered as a therapeutic option for this rare association.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Type 3 Choroidal Neovascularization Associated with Fundus Flavimaculatus

et al. 2009

View full text Add to dashboard Cite

show abstract

“…1,7,9 Noticeably, RAP is considered to represent up to 25% of occult or minimally classic CNV. 10,11 The indocyanine green angiography (ICG) can be helpful in detecting these lesions because neovascularization may appear like a focal area of hyperfluorescence, which is commonly referred as a "hot spot." [6][7][8] There is a controversy about which is the most appropriate treatment of RAP, although it is generally considered that RAP has a poor prognosis because it typically progresses to severe stages ending in a disciform scar.…”

mentioning

confidence: 99%

Long-Term Results of Intravitreal Ranibizumab, Intravitreal Ranibizumab With Photodynamic Therapy, and Intravitreal Triamcinolone With Photodynamic Therapy for the Treatment of Retinal Angiomatous Proliferation

Rouvas¹,

Chatziralli²,

Theodossiadis³

et al. 2012

Retina

View full text Add to dashboard Cite

show abstract

“…Combined therapy of bevacizumab with PDT showed resolution in 6 out of 7 patients (Fig. 1, 3-5; online suppl. Fig.…”

Section: Discussionmentioning

confidence: 99%

Treatment Effects in Retinal Angiomatous Proliferation Imaged with OCT Angiography

et al. 2018

View full text Add to dashboard Cite

Purpose: This prospective case series is aimed at exploring optical coherence tomographic angiography (OCT-A) as a treatment monitoring tool in patients treated for retinal angiomatous proliferation (RAP). Methods: Twelve treatment-naïve RAP patients were included, with a median age of 79 years (range 65–90). Patients were imaged with an experimental 1,040-nm swept-source phase-resolved OCT-A instrument before and after treatment. Treatment consisted of either intravitreal bevacizumab or triamcinolone injections with or without photodynamic therapy (PDT). Abnormal blood flow after treatment was graded as increased, unchanged, decreased, or resolved. Results: OCT-A images before and after treatment could be obtained in 9 patients. The median follow-up period was 10 weeks (range 5–19). After various treatments, the RAP lesion resolved in 7 patients, in 1 patient the OCT-A depicted decreased flow in the lesion, and 1 patient showed unchanged abnormal blood flow. Monotherapy with intravitreal bevacizumab injections resolved RAP in 1 out of 2 patients. Combined therapy of bevacizumab with PDT resolved RAP in 6 out of 7 patients. Conclusions: OCT-A visualized resolution of abnormal blood flow in 7 out of 9 RAP patients after various short-term treatment sequences. OCT-A may become an important noninvasive monitoring tool for optimizing treatment strategies in RAP patients.

show abstract

The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization

Abstract: d-ICGA is invaluable for early diagnosis of RAP in exudative age-related macular degeneration (ARMD). In our series, up to one fourth of type 2 occult CNV were in fact RAP.

Cited by 27 publications

References 15 publications

Type 3 Choroidal Neovascularization Associated with Fundus Flavimaculatus

Type 3 Choroidal Neovascularization Associated with Fundus Flavimaculatus

Long-Term Results of Intravitreal Ranibizumab, Intravitreal Ranibizumab With Photodynamic Therapy, and Intravitreal Triamcinolone With Photodynamic Therapy for the Treatment of Retinal Angiomatous Proliferation

Treatment Effects in Retinal Angiomatous Proliferation Imaged with OCT Angiography

Contact Info

Product

Resources

About